In 2022, Eli Lilly launched Tirzepatide, a novel dual GLP-1RA/GIPR agonist administered once weekly by subcutaneous injection that activates both GLP-1 and GIP receptors
We identify mitochondrial trifunctional protein- (MTP) as a binding partner of GLP-1(2836) and demonstrate that the ability of GLP-1(2836) to shift substrate utilization from oxygen-consuming fatty acid metabolism toward oxygen-sparing glycolysis and glucose oxidation and to increase cAMP levels is dependent on MTP
Initially, I was a bit skeptical, but I was committed to giving them a fair shot
According to the Wegovy label, fatigue occurs in approximately 11% of patients versus placebo, while Saxenda reports fatigue in 5-9% of patients
Moving forward, well review how bacteriostatic water works and its implications for peptide research and drug development
Compounded medications are not reviewed or approved by the FDA for safety, efficacy, or manufacturing quality and are not considered FDA-approved
